Day 2 - 11 June 2014

8:00 - 9:30	Registration
09:30 - 10:10 Plenary Session: Chair: Prof. Benjamin Dekel	Regenerative Medicine: Current Concepts and Changing Trends Dr. Anthony Atala, MD Director, Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA
10:10 - 10:40	Coffee Break
	Hall A - Rayman Central	Hall B - Rayman West	Hall C - Rayman East
10:40 - 12:20	Session F: Stem Cells in Drug Screening and Discovery Chair: Dr. Arik Hasson Co-Chair: Dr. Yaakov Nahmias	Session G: Cell Therapy in CNS Diseases Chair: Prof. Dani Offen	Session H: Cell Therapy in Diabetes and Metabolic Diseases Chair: Prof. Sarah Ferber
10:40 - 11:00 Keynote Lectures	Human Stem Cells in Disease Modeling and Drug Screening Prof. Nissim Benvenisty Stem Cell Unit, Genetics, Hebrew University of Jerusalem, Jerusalem, Israel	Preserving Vision Using Human Embryonic Stem Cell Derived Retinal Pigment Epithelium Cells Prof. Benjamin Reubinoff OB/GYN Human Embryonic Stem Cell Research Center, Hadassah Medical Center, Jerusalem, Israel	Introduction of a New Isolation Method for Clonal Mesenchymal Stem Cells and lleviation of Acute Pancreatitis by Human Clonal Mesenchymal Stem Cells in Animal Models Prof. Sun Song Translational Research Center, Inha University School of Medicine, Incheon, Korea
11:00 - 11:20	Post-Partum Microbial-Derived Cues Drive Hepatic Maturation Of Embryonic Stem Cells In Vitro: Applications In Predictive Toxicology Dr. Yaakov Nahmias Bioengineering, Hebrew University Of Jerusalem, Mevaseret Zion, Israel	Clinical Trials with Autologous Bone Marrow-Derived Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients with Amyotrophic Lateral Sclerosis (ALS) Dr. Yael Gothelf BrainStorm Cell Therapeutics, Petach Tikva, Israel	Autologous Cell Replacement Therapy for Diabetics by Reprogramming Adult Tissues Prof. Sarah Ferber Orgenesis/Sheba Medical Center
11:00 - 11:20			Serum-Free Media Development & Optimization: From a Medical Media Manufacturer’s Perspective Kim Ly Irvine Scientific, USA
11:20 - 11:40	Embryonic Stem Cells for Screening Applications: from Drugs to Basic Biology Prof. Eran Meshorer Department of Genetics, The Hebrew University of Jerusalem, Israel	Adult Human Oral Mucosa Stem Cells as Therapeutic Agents for Parkinson’s Disease Dr. Javier Ganz Tel Aviv University, Israel	Nature Derived Biomaterials as Platform for Cell Based Delivery and Therapy Prof. Marcelle Machluf Biotechnology and Food Engineering, Technion, Haifa, Israel
11:40 - 12:00	Drug Screening Assays Using Oligodendrocyte Progenitors Cells Derived from Human Pluripotent Stem Cells Dr. Michal Izrael Kadimastem, Nes-Ziona, Israel	In-Vitro Neural Differentiation of Fragile X Syndrome Human Embryonic Stem Cells as a Valuable Model for Drug Screening Michael Telias Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel	The Developmental Potential of IPSCS Is Greatly Influenced by the Selection of the Reprogramming Factors Dr. Yossi Buganim Developmental Biology and Cancer Research, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
12:00 - 12:20	Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Lili Barad Physiology, Faculty of Medicine, Technion, Haifa, Israel	Preclinical Stem Cells Studies: Administration and Distribution Considerations in Relation to Efficacy Timelines Prof. Ronnie Levy Pharmaseed, Ness Ziona, Israel	Bio-Artificial Pancreas – Regulatory Challenges (an ATMP/device combination product) Rivka Zaibel ADRES, Rehovot, Israel
12:20 - 12:45 Plenary Session: Chair: Prof. Ella Naparstek	Are Hematopoietic Stem Cells Really Stem Cells? Dr. Robert Gale Department of Medicine, Imperial College London, London, UK
12:30 - 14:00	Lunch Break
14:00 - 14:40 Plenary Session: Chair: Prof. Joseph Itskovitz- Eldor	Rigorous Translation of Stem Cell Science to Clinical Reality Prof. Silviu Itescu Chief Executive, Mesoblast, Australia
14:40 - 15:10	Coffee Break

Hall A - Rayman Central

Hall B - Rayman West

15:10 - 16:30

Session I:
Combination Products: Cells, Genes and Devices
Chair: Prof. Amos Panet

Session J:
Reconstructive Surgery and Adipose Tissue
Chair: Prof. Eyal Gur

15:10 - 15:30
Keynote Lectures

Adenoviral Vectors as Gene Carriers for Ex Vivo Gene Therapy - a Case Study for Fast and Efficient Bone Repair Using Adenovirus Vectors Expressing BMPs
Carl J. Christel
Sirion Biotech GmbH, Martinsried, Germany

Mesenchymal Stem Cells – from Cosmetic Treatments to Composite Tissue Allotransplantation
Prof. Eyal Gur
Plastic Surgery Department of The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

15:30 - 15:50

Biopump: A Novel Platform for Controlled and Sustained Delivery of Therapeutic Proteins- From Concept to the Clinic
Dr. Reem Miari
R&D, Medgenics Medical, Misgav, Israel

Inhibition of Composite Tissue Allograft Rejection by Adipose Derived Mesenchymal Stem Cells (ASCs): Intragraft Administration as a Way to Improve the in vivo Bioavailability of ASCs
Dr. Nir Shani
The Laboratory of Microsurgery and Plastic Surgery, The Tel Aviv Sourasky Medical Center, Israel

15:50 - 16:10

RNAi-Based Medicine for Solid Tumors: Clinical Evidences from Treatment of Pancreatic Cancer
Dr. Amotz Shemi
Silenseed, Jerusalem, Israel

Some Thoughts and Considerations on Stem Cell Therapy
Prof. Avinoam Kadouri
Rainbow Biotechnologies, Switzerland

16:10 - 16:30

Development of Oncolytic Viruses Against Solid Tumors
Prof. Amos Panet
Biochemistry, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel

Reconstruction of Complicated Defects of the Abdominal Wall Using Engineered Vascularized Tissues
Dr. Dana Egozi
Plastic And Reconstructive Surgery, Kaplan , Rehovot, Israel

16:30 - 16:50

Fat and Enhanced Fat Grafting in Reconstructive Surgery of the Breast
Prof. Michael Scheflan
Tel Aviv, Israel

16:50 – 17:00

Closing remarks

Dr. Avi Treves
Sheba Medical Center,
Chairman, Israstem 2014, Israel

Prof. Ella Naparstek
Tel Aviv Medical Center,
Co-Chairman, Israstem 2014,
Israel

Prof. Joseph Itskovitz-Eldor
Faculty of Medicine Technion, Israel
Co-Chairman, Israstem 2014,
Israel

This program is subject to change

<table style="border-color: #5c5d5b; border-width: 1px; border-style: solid;" border="1" cellpadding="5">
<tbody>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">8:00-9:30</td>
<td colspan="3" bgcolor="#D3DEDF" valign="top">Registration</td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">09:30 - 10:10 Plenary Session: Chair: Avi Treves</td>
<td colspan="3" bgcolor="#FFF0D2" valign="top"><img style="margin: 10px; float: left;" alt="Caplan 2012" src="/images/Caplan_2012.jpg" height="75" width="61" /><a href="/israstem-abs/out_of_pdf/adultmscsth_Arnold_Caplan.pdf" target="_blank">Adult MSCs: The New Medicine </a> Arnold Caplan Biology, Case Western Reserve University, Cleveland, USA <img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">10:10 - 10:40</td>
<td colspan="2" bgcolor="#FFFF99" valign="top">Coffee break</td>
</tr>
<tr bgcolor="#D3DEDF">
<td colspan="3" bgcolor="#99CC00" height="3" nowrap="nowrap"></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">10:40-12:20</td>
<td bgcolor="#E4E9D8" valign="top" width="50%">
<div>
<div><img style="margin-left: 10px; margin-right: 10px; float: left;" alt="Yehudit Cohen Sheba Tissue Banks" src="/images/Israstem13/Yehudit_Cohen_Sheba_Tissue_Banks.jpg" height="78" width="56" />Session E: Translational Research & Bio Banking Chair: Yehudit Cohen Scientific Director - Institutional Tissue Banks, Sheba Medical Center, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></div>
</div>
</td>
<td bgcolor="#E4E9D8" valign="top" width="50%"><img style="margin-left: 10px; margin-right: 10px; float: left;" alt="אריק חסון" src="/images/Israstem13/%D7%90%D7%A8%D7%99%D7%A7_%D7%97%D7%A1%D7%95%D7%9F.jpg" height="77" width="55" />Session F: Supporting Environment Chair: Arik Hasson Executive VP, Research & Development, Kadimastem Ltd., Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">
10:40 - 11:00  
Keynote Lectures </td>
<td bgcolor="#FFF0D2" valign="top"><a href="/israstem-abs/out_of_pdf/stemcellderiv_Marcelle_Machluf.pdf" target="_blank">Stem Cell Derived Nano-Vesicles, a New Platform Targeting the Tumor Bed </a> Marcelle Machluf Faculty of Biotechnology and Food Engineering, Institute of Technology, Haifa, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
<td bgcolor="#FFF0D2" valign="top"><a href="/israstem-abs/out_of_pdf/bringingcellt_Dirk_Balshuesemann.pdf" target="_blank">Bringing Cell Therapies into Clinical Routine</a> Dirk Balshuesemann Clinical Business, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany <img src="http://isranalytica.org.il/images/DE-flag.gif" height="23" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">11:00 - 11:20</td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/humanumbilical_Arnon_Nagler.pdf" target="_blank">Human Umbilical Cord Blood: More than a Source of Hematopoietic Stem Cells: Neurological Potential</a> Arnon Nagler Chaim Sheba Medical Center, Ramat Gan, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> </td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/buildingbridge_Thomas_Fellner.pdf" target="_blank">Building Bridges from Research to Therapy: Enabling the Utilization of Human Induced Pluripotent Stem Cells for Clinical Therapies</a> Thomas Fellner Pluripotent Stem Cell Innovation Center, Lonza, Inc., Walkersville, USA <img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">11:20 - 11:40</td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/theroleofplu_Nissim_Benvenisty.pdf" target="_blank">The Role of Pluripotent Stem Cells in Modeling Human Disorders and in Drug Screening</a> Nissim Benvenisty Stem Cell Unit, Genetics, Hebrew University, Jerusalem, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> </td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/currentregulat_Alan__Moore.pdf" target="_blank">Current Regulatory and cGMP Compliance Trends for Cellular Therapeutics and the Challenges in </a><a href="/israstem-abs/out_of_pdf/currentregulat_Alan__Moore.pdf">Translation to Late-Stage Commercial-Ready Manufacturing</a> Alan Moore VP Testing and Cell Services, WuXi AppTec  Philadelphia, USA <img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">11:40 - 12:00</td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/buildingqualit_Katheryn_Shea.pdf" target="_blank">Building Quality Biological Collections to Maximize Use</a> Katheryn Shea Precision Bioservices, Inc., Frederick, USA <img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /> </td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/intellectualpr_Hadassa_Waterman.pdf" target="_blank">Intellectual Property Issues Related to </a><a href="/israstem-abs/out_of_pdf/intellectualpr_Hadassa_Waterman.pdf">Cell-Based Inventions</a> Hadassa Waterman Biotech, Ehrlich and Fenster, Ramat Gan, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">12:00 - 12:20</td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/ipsstemcellb_Ida_Biunno.pdf" target="_blank">IPS Stem Cell Banking</a> Ida Biunno IRGB, IRGB-CNR, Milan, Italy <img src="http://isranalytica.org.il/images/italy-flag.jpg" alt="italy" height="23" width="35" /> </td>
<td valign="top"><a href="/israstem-abs/out_of_pdf/stemcellsinp_Judith_Ben-Porath.pdf" target="_blank">Stem Cells in Preclinical Studies: Choosing the </a><a href="/israstem-abs/out_of_pdf/stemcellsinp_Judith_Ben-Porath.pdf">Optimal Animal Model</a> Judith Ben-Porath Pharmaseed, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">12:20 - 14:00</td>
<td colspan="3" bgcolor="#FFFF99" valign="top">Lunch break</td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">14:00 - 14:40 Plenary Session: Chair: Avi Treves</td>
<td colspan="3" bgcolor="#FFF0D2" valign="top"><img style="margin: 10px; float: left;" alt="ZE photo" src="/images/Israstem13/ZE_photo.jpg" height="84" width="60" /> <a href="/israstem-abs/out_of_pdf/thet-bodyappr_Zelig_Eshhar.pdf" target="_blank">The T-Body Approach: From the Mouse Cage to The Patient’s Bed</a> Zelig Eshhar Immunology, Weizmann Institute, Rehovot, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">14:40 - 15:10</td>
<td colspan="2" bgcolor="#FFFF99" valign="top">Coffee break</td>
</tr>
<tr bgcolor="#99CC00">
<td colspan="3" height="3" nowrap="nowrap"></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">15:10-16:30</td>
<td bgcolor="#E4E9D8" valign="top"><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" />Session G: 
 Funding 
 Chair: Anat Naschitz 
 Managing Director, OrbiMed Advisors, LLC 
 </td>
<td colspan="2" bgcolor="#E4E9D8" valign="top"><img style="margin: 10px; float: left;" alt="IMG 2381" src="/images/Israstem13/IMG_2381.JPG" height="75" width="58" />Session H: Company-Regulator Interface Chair: Ofra Axelrod Deputy Director, The Institute for Standardization and Control of Pharmaceuticals, Israeli MOH, Israel <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">15:10 - 15:30 Keynote Lectures</td>
<td bgcolor="#FFF0D2" valign="top">
The Office of the Israel Chief Scientist Incentives for R&D in Cell Therapy, Regenerative Medicine and Stem Cells 
Janette Lazarovits 
The Office of the Chief Scientist</td>
<td colspan="2" rowspan="4" valign="top" bgcolor="#FFFFFF"><a href="/israstem-abs/out_of_pdf/theregulatory_Margarida__Menezes_Ferreira.pdf" target="_blank">The Regulatory Challenges for the Approval of Advanced Therapies in Europe </a> 
 Margarida Menezes Ferreira 
 Medicines Evaluation Department, INFARMED, 
 National Authority of Medicines and Health Products, Lisboa, Portugal 
 Member of the Committee for Advanced Therapies and of the Biologics Working Party/CHMP – EMA, Portugal 
 <img title="7628969_flagbig1.gif" alt="7628969_flagbig1.gif" src="http://dr.doali.co.il/admin/temp/newsletters/1006/7628969_flagbig1.gif" height="23" width="35" /> 
 
 <a href="/israstem-abs/out_of_pdf/fdaisitrea_Joyce_Frey-Vasconcells.pdf" target="_blank">FDA: Is it Really a Black Hole?</a> 
 Joyce Frey-Vasconcells 
 Frey-Vasconcells Consulting, LLC 
 
 
 <a href="/israstem-abs/out_of_pdf/euregulators_Anne__Dupraz-Poiseau.pdf" target="_blank">EU Regulators’ Expectations for a Stem Cell Based Product Development a Focus on CMC and NC Development</a> 
 Anne Dupraz-Poiseau 
 Voisin Consulting Life Sciences, France 
 <img src="/images/frlarge.gif" alt="france" height="23" width="34" />
A Harmonized Approach in Regulation of PLX-PAD 
 Racheli Ofir 
 Pluristem, MATAM  Park, Haifa, Israel (15 min.)
<img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /> 
     
 
 
<img style="float: left;" alt="104714569" src="/images/icons/104714569.jpg" height="76" width="96" />Special Panel-Meet the Regulator: 
 Audience Questions and Open Discussion 
 
</td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">15:30 - 15:50</td>
<td bgcolor="#FFFFFF" valign="top">Pontifax, Vision and Investment Strategy 
Silvia Noiman 
Pontifax, Israel 
<img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">15:50 - 16:10</td>
<td bgcolor="#FFFFFF" valign="top"><a href="/israstem-abs/out_of_pdf/syndicateinnov_Alain_Vertes.pdf" target="_blank">Syndicate Innovation Venturing</a> 
Alain Vertes 
Park BioVentures, New York, NY, USA 
<img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">16:10 - 16:30</td>
<td bgcolor="#FFFFFF" valign="top"><a target="_blank" href="/israstem-abs/out_of_pdf/theisraelicel_Avi__Treves_.pdf">The Israeli Cell Therapy Landscape</a> 
Avi Treves 
Sheba Cancer Research Center, Israel 
<img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">16:30 – 17:10 
Plenary session: 
Chair: 
Michel Revel</td>
<td colspan="3" valign="top"><img style="margin: 10px; float: left;" alt="EvaFeldman-BannerPhoto" src="/images/Israstem13/EvaFeldman-BannerPhoto.jpg" height="83" width="61" /><a href="/israstem-abs/out_of_pdf/intraspinalste_Eva_Feldman,_MD,_PhD.pdf">Intraspinal Stem Cell Transplantation in ALS: Results of the First Phase 1 FDA Clinical Trial</a> Eva Feldman  Neurology University of Michigan, Ann Arbor, USA <img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /> </td>
</tr>
<tr>
<td bgcolor="#D3DEDF" nowrap="nowrap">17:10 – 17:25</td>
<td colspan="3" valign="top"><img style="margin: 10px; float: left;" alt="Shosh Merchav" src="/images/Shosh_Merchav.jpg" height="81" width="64" />Closing Shosh Merchav CEO, Multifacet Biosolutions Ltd., Israel, Co- Chairman Israstem 2013 <img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></td>
</tr>
</tbody>
</table>